GLYCONEX INCORPORATION

FINANCIAL STATEMENTS AND REPORT OF INDEPENDENT ACCOUNTANTS

DECEMBER 31, 2019 AND 2018

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.



REPORT OF INDEPENDENT ACCOUNTANTS TRANSLATED FROM CHINESE

To GlycoNex Incorporation

Opinion

We have audited the accompanying balance sheets of GlycoNex Incorporation (the "Company") as at December 31, 2019 and 2018, and the related statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2019 and 2018, and its financial performance and its cash flows for the years then ended in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the "Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants" and generally accepted auditing standards in the Republic of China (ROC GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Professional Ethics for Certified Public Accountants in the Republic of China (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.



The key audit matters of the Company for the year ended December 31, 2019 are as follows:

Existence and occurrence of bank deposits

Description

Refer to Notes 4(5) and (8) for accounting policies on cash and cash equivalents and financial assets at amortised cost and Notes 6(1) and (3) for account details in the financial statements.

As at December 31, 2019, the balances of cash and cash equivalents and financial assets at amortised cost totalled NT\$160,036 thousand, constituting 12% of total assets. As the bank deposits are high risk in nature, are material to the financial statements and the determination as to whether the bank deposits qualify as cash equivalent relies on management judgement, we consider the existence and occurrence of bank deposits a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the key audit matter mentioned above:

- 1. We sent out audit confirmations to banks and financial institutions for specific agreements and bank accounts, in order to confirm the existence, rights and obligations of the related cash and cash equivalents.
- 2. We checked the term of the time deposits to determine whether it meets the definition of cash equivalents.
- 3. For period end bank reconciliations, we compared the account balance to the general ledger, as well as the balance of the bank account to bank statements, deposit books or bank confirmations, and we checked the accuracy and reasonableness of the bank reconciliation adjustments.
- 4. Inspected the source documents of significant cash receipts and payments to verify whether the transactions are for business purposes.

Impairment of property, plant and equipment and investment property

Description

Refer to Notes 4(14) and (15) for the accounting policy on property, plant and equipment and investment property, Note 5 for the uncertainty of accounting estimates and assumptions in relation to impairment, and Notes 6(6) and (8) for account details in the financial statements.

As at December 31, 2019, the balances of property, plant and equipment and investment property totalled NT\$1,125,385 thousand, constituting 85% of total assets. Management has estimated the



abovementioned assets' recoverable amounts because the Company has not generated profit during the research and development stage and there is indication that the assets might have been impaired. The calculation of recoverable amounts rely on subjective judgements and thus underly great uncertainty. Given the material amount of abovementioned assets, we consider the impairment of the assets a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the key audit matter mentioned above:

- 1. We obtained the evaluation form for impairment indication from the management to examine its reasonableness.
- 2. We ascertained whether the fair value of property, plant and equipment is properly referenced to sources such as recent public transactions of similar real estate as well as quotation of business facilities.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Company's financial reporting process.



Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ROC GAAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ROC GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- 5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

TENG, SHENG-WEI

YU, SHU-FEN

for and on behalf of PricewaterhouseCoopers, Taiwan March 25, 2020

The accompanying financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

GLYCONEX INCORPORATION BALANCE SHEETS DECEMBER 31, 2019 AND 2018 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Assets	Notes		December 31, 2019 AMOUNT %		December 31, 201 AMOUNT		
	Current assets	Notes		AMOUNT		(X)	AMOUNT	<u>%</u>
1100	Cash and cash equivalents	6(1)	Ф	110 226	0	ф	244 100	
	~		\$	112,336	8	\$	244,180	16
1136	Financial assets at amortised	6(3)						
	cost - current			47,700	4		82,200	5
1170	Accounts receivable, net			-	-		28	-
1200	Other receivables			94	-		98	-
1220	Current income tax assets			245	-		320	-
1410	Prepayments			5,592	-		12,522	1
1470	Other current assets			20			349	
11XX	Total current assets		_	165,987	12		339,697	22
	Non-current assets							
1517	Financial assets at fair value	6(4)						
	through other comprehensive							
	income - non-current			13,151	1		14,103	1
1550	Investments accounted for under	6(5)						
	equity method			20,414	2		21,134	1
1600	Property, plant and equipment	6(6)		1,090,989	82		1,131,509	73
1760	Investment property - net	6(8)		34,396	3		35,810	2
1780	Intangible assets	6(9)(26)		5,159	-		16,289	1
1840	Deferred income tax assets	6(25)		1,339	-		1,829	
1900	Other non-current assets			755			1,430	
15XX	Total non-current assets			1,166,203	88		1,222,104	78
1XXX	Total assets		\$	1,332,190	100	\$	1,561,801	100

(Continued)

GLYCONEX INCORPORATION BALANCE SHEETS DECEMBER 31, 2019 AND 2018 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		2021.00	December 31, 2019					
-	Liabilities and Equity Current liabilities	Notes		AMOUNT	_%_	-	AMOUNT	%
2130	Contract liabilities - current	6(19)	\$	117		\$	61	
2150	Notes payable		Ψ		-	φ		-
2200	Other payables	6(11)		2,203	-		2,725	-
2300	Other current liabilities			17,751	1		15,584	1
21XX	Total current liabilities		-	1,444		-	1,435	
	Non-current liabilities		3	21,515	1		19,805	1
2600	Other non-current liabilities	6(12)(13)		9,820	1		9,545	1
25XX	Total non-current liabilities			9,820	1	-	9,545	1
2XXX	Total liabilities		-	31,335	2	0	29,350	2
	Equity			31,333			27,330	
	Share capital	6(14)(15)						
3110	Common stock			761,610	57		765,035	49
3140	Advance receipts for share capital			14,314	1		_	
	Capital Reserve	6(14)(16)		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-			
3200	Capital surplus			782,240	59		1,103,837	71
	Retained earnings	6(17)		,,			1,105,057	
3350	Accumulated deficit		(251,564) (19)	,	317,218) (20)
	Other equity interest	6(18)	•	,	/		517,5107(20,
3400	Other equity interest		(5,745)	- (,	11,350) (1)
3500	Treasury stocks	6(15)	`	-	- (7,853) (1)
3XXX	Total equity		-	1,300,855	98		1,532,451	98
	Significant contingent liabilities	9	-	1,300,033				
	and unrecognised contract							
	commitments							
	Significant events after the	11						
	reporting period							
3X2X	Total liabilities and equity		\$	1,322,190	100	\$	1,561,801	100

GLYCONEX INCORPORATION STATEMENTS OF COMPREHENSIVE INCOME YEARS ENDED DECEMBER 31, 2019 AND 2018 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

				2019			2018	
	Items	Notes		AMOUNT	%		AMOUNT	%
4000	Operating revenue	6(19)	\$	734	100	\$	926	100
5000	Operating costs	6(23)(24)	(585)	(80)	(448) (49)
5950	Gross profit		`	149	20	`	478	51
	Operating expenses	6(23)(24)				-	170	
6100	Selling expenses		(2,168)	(295)	(4,181) (451)
6200	General and administrative expenses		(48,923)			48,232) (5209)
6300	Research and development expenses		(218,911)			269,642) (
6000	Total operating expenses		(270,002)			322,055) (
6900	Operating loss		`	269,853)		-	321,577) (34728)
	Non-operating income and expenses		`	205,000)		`	321,377)	34720)
7010	Other income	6(3)(7)(20)		25,155	3427		22,222	2400
7020	Other gains and losses	6(2)(21)	(1,983) ((18,979) (2050)
7050	Finance costs	6(22)	(5)		(5)	2030)
7070	Share of (loss) profit of associates and joint ventures accounted for under the equity method		,	3,		(3)	-
7000	Total non-operating income and expenses		(51) (β	743	80
7900	Loss before income tax			23,116	3150		3,981	430
7950	Income tax (expense) benefit	6(25)	(246,737) ((317,596) (34298)
8200	Net loss		(490) (653	71
	Other comprehensive income (loss)		(<u>\$</u>	247,227) (33682)	(\$	316,943) (34227)
	Components of other comprehensive income (loss) that will not be reclassified to profit or loss							
8311	Actuarial losses on defined benefit plans	6(13)	(\$	564) (77)	(\$	275) (30)
8316	Unrealised gains from financial assets measured at fair value through other comprehensive income	6(4)(18)		050)	100			70
	outer comprehensive income		(952) (130)		734	79
8300	Total other comprehensive (loss) income for the year		(\$	1,516) (207)	\$	459	49
8500	Total comprehensive loss for the year		(\$	248,743) (33889)	(\$	316,484) (34178)
	Loss per share (in dollars)	6(27)	-					
9750	Basic loss per share	es unes transitions	(\$		3.26)	(\$		4.18)
9850	Diluted loss per share		(\$		3.26)	-		4.18)
			. *		3.20)	, Ψ		

GLYCONEX INCORPORATION STATEMENTS OF CHANGES IN EQUITY YEARS ENDED DECEMBER 31, 2019 AND 2018 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		Ca	Capital		Capital Reserves			Other Equity Interest			
	Notes	Common stock	Advance receipts for share capital	Capital	Restricted stocks to employees	Accumulated deficit	Unrealised gains or losses on financial assets measured at fair value through other comprehensive income	Unrealised gains or losses on available-for-sale financial assets	Uneamed compensation of restricted stock to employees	Treasury	Total equity
2018 Balance at January 1, 2018 Effect on retrospective application and retrospective		\$ 764,985	€9	\$ 1,295,936	\$ 10,557	(\$ 203,641)	€9	(\$ 4,706)	(\$ 14,030) (\$	(\$ 7,853)	\$ 1,841,248
restatement Balance after restatement on January 1, 2018		764,985		1 295 936	10.557	- 203 641 1	(4,706)	4,706	- 000 71	1 0	
Net loss for the year			'		100,01	(316,943)	1,100	' '	14,030)	(7,853)	1,841,248
Other comprehensive income (loss) for the year Total comprehensive loss	(81)				1 1	(275)	734	1	1		459
Capital surplus used to offset against accumulated	6(17)					()11,110)	+67		'	1	316,484)
uction Issuance of restricted stocks to employees	6(14)	1,750		(203,641)	3.410	203,641		()	- 5 160)	1	15 2
Vesting of restricted stocks to employees	6(14)	1	ì	2,639	(2,639)	,	•		7,100	. ,	
Returement of restricted stocks to employees	6(14)	(1,700)	- (ī	(2,425)	3	1		4,125	1	e a
Compensation costs of restricted stocks to employees	6(14)				1	1	•	•	7,687	d	7.687
Balance at December 31, 2018		\$ 765,035	5	\$ 1,094,934	\$ 8,903	(\$ 317,218)	(\$ 3,972)	€5	(\$ 7,378)	(\$ 7,853)	\$ 1,532,451
<u>2019</u> Balance at January 1 2019		365 035	¥	¢ 1 004 024	C			4			
Net loss for the year			9	- 1,094,934	6,903	(3 - 317, 218)	(\$ 3,972)	·	(\$ 7,378)	(\$ 7,853)	\$ 1,532,451
Other comprehensive loss for the year	6(18)	1	1	1	1	(564)	(952)	,			(177,177)
Total comprehensive loss		'	'	1	1	(247.791)	(952)	'			1,310)
Advance receipts for share capital		L	14,314	1					'		14 314
Capital surplus used to offset against accumulated	(11)									•	14,014
deficit	;	1	1	(317,218)	ı	317,218	1	ä	10	r	1
Vesting of restricted stocks to employees	6(14)	il .	,	2,198	(2,198)	ï	1	i		r	,
Returement of restricted stocks to employees	6(14)	(1,385)	-	313	(2,339)		i	Ü	3,724	1	•
Compensation costs of restricted stocks to employees	6(14)	1	9		•		i	ì	2,833	r	2,833
Keturement of treasury stock	6(15)					(3,773)	'	1	1	7,853	
Balance at December 31, 2019		\$ 761,610	\$ 14,314	\$ 777,874	\$ 4,366	(\$ 251,564)	(\$ 4,924)	· ·	(\$ 821)	·	\$ 1,300,855

The accompanying notes are an integral part of these parent company only financial statements.

GLYCONEX INCORPORATION STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2019 AND 2018 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes		2019		2018
CASH FLOWS FROM OPERATING ACTIVITIES					
Loss before tax		(\$	246,737)	(\$	317,596)
Adjustments		(Ψ	210,737)	(Ψ	317,370)
Adjustments to reconcile profit (loss)					
Contract liabilities to revenue		(61)	(92)
Depreciation and amortisation	6(23)	(54,906	(56,876
Impairment loss	6(21)		54,700		18,190
Net gain on financial assets at fair value through profit or loss	6(21)			(3)
Share of profit or loss of associates and joint ventures accounted				(3)
for under the equity method			51	(743)
Interest income	6(20)	(2,527)	(3,743)
Interest expense	6(22)	(2,327)	(
Compensation costs of restricted stocks to employees	6(14)		2,833		7 697
Changes in operating assets and liabilities	0(14)		2,033		7,687
Changes in operating assets and habilities Changes in operating assets					
Financial assets at fair value through profit or loss - current					50.007
Accounts receivable, net			-		50,807
Other receivables			28	,	172
			30	(23)
Prepayments Other current assets			6,930		106
			329		884
Changes in operating liabilities					
Contract liabilities - current			117		61
Notes payable			204	(227)
Other payables			1,999		2,581
Other current liabilities			8		210
Other non-current liabilities		(118)	(109)
Cash outflow generated from operations		(182,003)	(184,957)
Interest received			2,501		3,905
Income tax received			182		259
Income tax paid		(107)	(138)
Dividends received			668		296
Net cash flows used in operating activities		(178,759)	(180,635)
CASH FLOWS FROM INVESTING ACTIVITIES		874		155	
Decrease in financial assets measured at amortised cost - current			34,500		1,052
Acquisition of property, plant and equipment	6(29)	(1,496)	(3,220)
Decrease in refundable deposits		,	-	`	120
Increase in other non-current assets		(236)	(493)
Net cash flows provided by (used in) investing activities		\	32,768	(2,541)
CASH FLOWS FROM FINANCING ACTIVITIES		-	32,700	(2,541)
(Decrease) increase in deposits received		(167)		1,124
Advance receipts for share capital		(14,314		1,124
Net cash flows provided by financing activities					1 124
Net decrease in cash and cash equivalents		,	14,147	,——	1,124
		(131,844)	(182,052)
Cash and cash equivalents at beginning of year		<u>_</u>	244,180	ф.	426,232
Cash and cash equivalents at end of year		\$	112,336	\$	244,180